-
Though Safe and Tolerable, Nilotinib Does Not Show Promise for Benefit in Phase II Nilotinib for Parkinson’s Disease (NILO-PD) Trial
December 5, 2019
… study strictly excluded those with heart issues or other health challenges No observed clinical benefit nor … their Parkinson’s treatment regimen work closely with their health care provider before doing so. While nilotinib was … in the study population, the study was strict with health history, excluding those who may have heart issues or …
-
News in Context: What Syngenta’s Decision to End Paraquat Production Means for Parkinson’s Risk
March 4, 2026
… news into context, we spoke with Grant Cope (GC), Environmental Health Policy Lead at MJFF. MJFF: What exactly did Syngenta … market or prevent exposure. In fact, according to environmental groups, Sinochem exports tens of millions of pounds …
-
AMP PD Knowledge Platform
… The Michael J. Fox Foundation, National Institutes of Health, the U.S. Food and Drug Administration, Aligning … through the Foundation of the National Institutes of Health (FNIH). Access the AMP PD Knowledge Platform AMP PD …
-
The Michael J. Fox Foundation Wins 2023 Silver Anthem Award for Its Landmark Study: PPMI
February 27, 2023
… companies and organizations. PPMI wins recognition in the health research projects and publications category for its ability to educate and raise interest around a health cause. And PPMI is doing just that! Since 2010, …
-
In Memoriam: MJFF Mourns Loss of Parkinson’s Research Leader Nir Giladi, MD
… achievements, Dr. Giladi was a dedicated leader in public health, serving as the Medical Professions Ombudsman for Israel’s Ministry of Health. His pioneering contributions spanned more than two …
-
Real Talk from Participants
… are studying the link between sense of smell and brain health. People with and without Parkinson's can help by …